Pfizer to seek FDA approval for a COVID-19 vaccine booster dose

A third COVID-19 booster dose given about six months after the second shot improves vaccine efficacy

Pfizer and BioNTech say that a third COVID-19 booster dose given about six months after the second shot improves vaccine efficacy against new coronavirus variants and that this is backed by initial data from their study on booster shots.
While the COVID-19 vaccine remains 95% effective in preventing serious cases, efficacy against catching the disease has started to decrease in populations in the UK and Israel about six months after getting the second vaccine shot, according to Pfizer Chief Scientific Officer Mikael Dolsten. The company said it plans to seek emergency authorization approval from the US Food and Drug Administration in August, according to The Associated Press.
While the COVID-19 vaccine remains 95% effective in preventing serious cases, efficacy against catching the disease has started to decrease in populations in the UK and Israel about six months after getting the second vaccine shot
Pfizer CEO Albert Bourla said, "A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed. And again, the variants will play a key role."
representative image
Image: representative image
The comment comes after Johnson & Johnson CEO Alex Gorsky told CNBC in February that people may need to get vaccinated against Covid-19 annually, just like seasonal flu shots.




Be the first to start a discussion here. Sign-in to write a comment now!